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Wang Zhang2, Hua Yu2, Donald L. Morton3 and Dave S.B. Hoon1
B7-H3, a cell surface transmembrane glycoprotein, was assessed for its functional and prognostic role in
cutaneous melanoma progression. B7-H3 expression in melanoma cells was shown to be related to specific
downstream signal transduction events as well as associated with functional epigenetic activity. B7-H3 expression
and prognostic utility were shown by reverse transcription and real-time PCR and immunohistochemistry analysis
on individual melanoma specimens and then verified in clinically annotated melanoma stage III and stage IV
metastasis tissue microarrays in a double-blind study. B7-H3 messenger RNA expression was shown to be
significantly increased with stage of melanoma (Po0.0001) and significantly associated with melanoma-specific
survival in both stage III (Po0.0001) and stage IV (Po0.012) melanoma patients. B7-H3 expression was related to
migration and invasion; overexpression of B7-H3 increased migration and invasion, whereas knockdown of B7-H3
reduced cell migration and invasion. MiR-29c expression was shown to inversely regulate B7-H3 expression.
Furthermore, we demonstrated that melanoma B7-H3 expression was correlated to phosphorylated signal
transducer and activator of transcription-3 activity level in melanoma tissues and cell lines. These studies
demonstrate that B7-H3 is a significant factor in melanoma progression and events of metastasis.
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INTRODUCTION
Melanoma is an aggressive form of skin cancer, having one of the
highest increasing incidence rates of any cancer in Caucasians
with a poor 5-year survival rate in patients with American Joint
Committee on Cancer (AJCC) stage III and IV (Balch et al., 2009).
It is difficult to predict melanoma recurrence after surgical resec-
tion of early-stage metastatic melanomas. Studies have shown
that immunoregulatory molecules can be expressed on human
tumor cells and have important roles in both tumorigenesis and
tumor progression (Flies and Chen, 2007; Zang and Allison,
2007; Goto et al., 2008; Hofmeyer et al., 2008; Sato et al., 2009;
Balkwill, 2011; Shiao et al., 2011; Taube et al., 2012).
B7 family members are known to modulate host immunity.
The prototype ligands of this family, B7-1 and B7-2, have
well-defined roles as essential co-stimulatory molecules
involved in T-cell regulation (Steinberger et al., 2004;
Cao et al., 2011). In contrast, the roles of the other B7-H
family molecules (i.e., B7-H3 and B7-H4) remain unclear
(Greenwald et al., 2005; Crispen et al., 2008). One of the B7
family members, B7-H3 (CD276), a type I transmembrane
protein, is expressed on dendritic monocytes, macrophages
and activates T cells (Chapoval et al., 2001; Hofmeyer
et al., 2008; Kobori et al., 2010). B7-H3 function is
suggested to have a role in regulating immune responses of
T cells (Leitner et al., 2009; Kobori et al., 2010). B7-H3
expression on tumor cells, including melanoma, has been
reported (Sun et al., 2006; Roth et al., 2007), and proposed
to have involvement in tumor cell escaping immune
surveillance and promoting immune tolerance (Petroff et al.,
2005; Hofmeyer et al., 2008).
We investigated several significant melanoma-related reg-
ulatory factors associated with B7-H3; one of which, the
downregulation of miR-29c has recently been implicated in
melanoma progression by our group (Nguyen et al., 2010). In
a recent report in neuroblastoma, miR-29 was shown to bind
to the B7-H3 30 untranslated region (Xu et al., 2009). We
hypothesized that B7-H3 expression on melanoma cells
regulates mechanisms associated with tumor progression and
its expression may be prognostic.
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RESULTS
B7-H3 mRNA expression in melanoma tissues
To examine B7-H3 expression relevance in melanomas, a
reverse transcription and real-time PCR (RT-qPCR) assay for
B7-H3 mRNA analysis was developed on paraffin-embedded
archival tissue (PEAT) melanomas. B7-H3 mRNA copy num-
ber distribution of nevi/benign lentigo melanocytes/normal
skins (seven nevi/benign lentigo and six normal skins),
primary, and metastatic melanomas are shown in Figure 1a.
Mean (±SD) relative B7-H3 mRNA copies in tumors from
AJCC stages I, II, III primary melanoma patients were 7.67
10 4±1.29 10 3 (n¼22), 2.2810 3±3.12103
(n¼ 14), and 1.71103±2.86103 (n¼ 21), respec-
tively. For AJCC stage III and IV metastatic tumors, B7-H3
mRNA copies were 4.7610 3±6.2310 3 (N¼23) and
5.10 10 3 ±4.74 103 (N¼20), respectively.
B7-H3 mRNA copy number distribution of nevi/benign,
primary, and metastatic melanomas are shown in Figure 1b.
B7-H3 mRNA copy numbers were significantly higher
(Po0.05) in melanomas compared with nevi/benign lentigo
melanocytes/normal skins, and significantly increased with
advancing stage. B7-H3 expression demonstrated to correlate
to melanoma progression.
B7-H3 protein expression in melanomas
To examine B7-H3 protein expression, we performed immu-
nohistochemistry (IHC) to evaluate primary melanomas (stage
II, n¼18; stage IIIp, n¼12), stage III lymph node (LN)
metastases (n¼20), stage IV distant metastases (n¼47), and
nevi (n¼ 17; Figure 2a–d). There was trend of higher B7-H3
protein expression with disease stage (stage II, P¼0.0002;
stage III, P¼0.0007; stage IIIm, Po0.0001; stage IV,
Po0.0001; Figure 2e). B7-H3 was significantly enhanced in
both primary and metastases compared with nevi (Po0.0001,
Figure 2f). Patients were divided into two groups according to
IHC intensity; tissues with a score of 2–3 were classified as the
high B7-H3 expression group, whereas those scoring 0–1 were
classified as the poor/no B7-H3 expression group. The level of
B7-H3 expression in different stage IV organ site metastasis
was not significantly different (Supplementary Figure S1
online). These results confirmed that B7-H3 expression levels
were elevated in melanoma, as compared with nevi, and not
related to the organ site of melanoma metastasis.
B7-H3 expression in melanoma tissue microarrays (TMAs) and
prognostic utility
We next assessed the prognostic value of B7-H3 in metastasis
using stage III and IV tumor tissue TMAs. B7-H3 expression
level of regional LN metastases and distant organ metastases
was assessed by IHC (Figure 3a) and correlated with mela-
noma-specific survival (MSS). Patients were divided into two
groups based on their B7-H3 expression levels as described
above. B7-H3 expression was a significant predictor of MSS in
the stage III TMA (Po0.0001; Figure 3b) and in the stage IV
TMA (P¼0.012; Figure 3c). The verification of IHC analyses
on the melanoma TMAs confirmed the findings of the indi-
vidual melanoma PEAT as well as demonstrated prognostic
value of B7-H3 in disease outcome for both stage III and IV
patients.
To further confirm the role of B7-H3 in prognosis of
different stage of metastatic melanoma, we analyzed B7-H3
protein expression by IHC in autologous pairs of stage III
melanoma LN metastases and metachronous stage IV distant
metastases from 32 patients within the stage IV TMA. Stage IV
metastases showed significantly higher expression of B7-H3
(P¼ 0.042) when compared with their autologous paired stage
III metastasis, further verifying elevation of B7-H3 expression
in melanoma progression (Figure 3d).
B7-H3 expression on melanoma cells
B7-H3 protein expression in melanoma cells was verified by
various approaches. Immunofluorescent staining of melanoma
lines showed strong B7-H3 protein expression on the cell
surface (Figure 4a). B7-H3 immunofluorescent analysis of
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Figure 1. B7-H3 messenger RNA (mRNA) expression in melanomas. (a) B7-H3 mRNA expression in American Joint Committee on Cancer stage I, II, III primary
melanomas, stage III, IV metastatic melanomas, and nevi/benign lentigo melanocytes/normal skin tissues. (b) B7-H3 mRNA expression in primary melanomas,
metastatic melanomas, and nevi/benign lentigo melanocyte/normal skin tissues. Horizontal bars indicate mean relative B7-H3 copy numbers.
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Figure 2. Immunohistochemistry (IHC) staining of B7-H3 of melanomas. (a–d) Representative IHC staining of B7-H3. (a) Negative control (primary antibody
isotype control). (b) Nevus. (c) Primary melanomas. (d) Metastatic melanomas. (e) B7-H3 expression (IHC score) in primary melanoma American Joint Committee
on Cancer (AJCC) stage II, III, metastatic melanoma AJCC stage III, IV, and nevus. (f) B7-H3 IHC score in primary melanomas, metastatic melanomas, and nevus.
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Figure 3. Melanoma-specific survival (MSS) in stage III and stage IV melanoma (tissue microarray, TMA) patients. (a) Representative TMA immunohistochemistry
(IHC) staining of B7-H3. (a1) Lymph node (LN) metastasis with absent expression of B7-H3. (a2) LN metastasis with weak expression of B7-H3. (a3) LN metastasis
with moderate expression of B7-H3. (a4) LN metastasis with strong expression of B7-H3. In figures a1–a4, bars indicate 200mm in length. Original
magnification  100. (b) Stage III TMA (n¼139) MSS comparing B7-H3 IHC score of 0–1 (no–weak) versus 2–3 (moderate–strong). (c) Stage IV TMA
(n¼ 169) MSS comparing B7-H3 IHC score of 0–2 (no–moderate) versus 3 (strong). (d) Analysis of B7-H3 IHC score between paired matched stage III LN
metastases and stage IV distant metastases from the same patient in the stage IV TMA. Horizontal lines represent average B7-H3 score among each stage.
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melanocytes showed no detection. We then assessed mela-
noma cell lines M-1, M-101, M-111, M-12, M-14, JK-0346,
and Mel-B, along with two donor peripheral blood leukocytes
as negative controls by flow cytometry. Flow cytometric
analysis showed that B7-H3 protein was highly expressed on
the cell surface of all melanoma lines (n¼ 7; Figure 4b,
Supplementary Figure S2 online).
Western blot analysis confirmed the expression of B7-H3
protein in melanoma. Melanoma cell lines M-101, M14, M24,
Wm266-4, JH-1173, along with three frozen metastases from
stage III and IV patients were assessed. B7-H3 protein
expression was confirmed in both melanoma lines and tissues
(Figure 4c), but not in melanocytes supporting PEAT IHC and
mRNA results.
MiR-29c regulates B7-H3
MiR-29c can have tumor suppressor function in that it is
significantly downregulated during melanoma progression
(Nguyen et al., 2010). MiR-29c was shown to directly target
B7-H3 30 untranslated region (Figure 5a). We focused on
miR-29c levels in melanomas relative to B7-H3. B7-H3 IHC
was performed on the same LN specimens in the TMAs as
those previously assessed by RT-qPCR for miR-29c expression.
MiR-29c expression level was found inversely correlated to
B7-H3 protein level (Spearman’s correlation, r¼  0.403,
Po0.0001; n¼ 90; Figure 5b).
To investigate the regulatory role of miR-29c in melanoma
B7-H3 expression, transfection studies were carried out on
M14, M101, and Wm266-4, which have high B7-H3 expres-
sion. Transfection of miR-29c mimic significantly reduced
B7-H3 expression (Figure 5c, Supplementary Figure S3A and B
online). B7-H3 mRNA and protein expression in M14 and
M101 transfected with miR-29c mimic were reduced 43-fold
compared with that in M14 and M101 transfected with
miR-29c negative control (Figure 5d and f, Supplementary
Figure S3C and D online).
Signal transducer and activator of transcription-3 (STAT3),
phosphorylated-STAT (p-STAT) expression were related to B7-H3
Recent studies demonstrate that poor melanoma prognosis
is associated with elevated p-STAT3 expression (Jensen
et al., 2011). We therefore explored the association between
p-STAT3 and B7-H3 expression. IHC staining of p-STAT3 in
B7-H3 high (score 3) LN metastases (n¼10) was compared
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Figure 4. B7-H3 expression in melanoma cells. (a) Immunohistochemistry (IHC) staining of a melanoma cell line (M14). Top left: bright field; top right: B7-H3;
bottom left: 40,6-diamidino-2-phenylindole (DAPI); bottom right: merged DAPIþB7-H3. Original magnification  400. (b) Flow cytometry analysis of B7-H3
expression (open histogram) versus antibody isotype controls (shaded histogram) in melanoma cell lines and normal peripheral blood leukocytes (PBL). (c) Western
blotting analysis of melanoma cell lines and tissues (T1–T3). Bar¼ 100mm.
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with those in B7-H3 low (score 0–1) LN metastases (n¼ 10).
Expression of p-STAT3 was significantly (P¼0.029) higher in
B7-H3 high-expression melanomas compared with B7-H3
low-expression melanomas. Our results demonstrated an
association of p-STAT3 and B7-H3 expression (Figure 5e).
Results from the miR-29c transfection studies demonstrated
miR-29c significantly reduced STAT3 and p-STAT3 expression
in the M14, M101, and Wm266-4 (Figure 5f, Supplementary
Figure S3D online).
To further confirm whether p-STAT3 was related to B7-H3
expression, we assessed level of stat3 and p-STAT3, and also
the level of their downstream target cyclin D1 in M14 B7-H3
small hairpin RNA (shRNA) stable cell clones. It was shown in
Figure 5g that level of STAT3, p-STAT3, and cyclin D1 was
reduced on knockdown of B7-H3 in melanoma cells. These
results suggested B7-H3 influences p-STAT3 activity support-
ing our other findings above.
B7-H3 function in melanoma cells
To explore the functions of B7-H3 in melanoma cell lines,
B7-H3 expression was assessed by western blotting. We found
all melanoma lines except M219 expressed high levels of
B7-H3 (Figure 6a left). To further examine B7-H3 relevance,
we knocked-down B7-H3 by B7-H3 shRNA in M14, and
overexpressed B7-H3 by transfecting B7-H3 expression vector
in M219. B7-H3 knock-down M14 stable clones (M14 B7-H3
shRNA) and B7-H3 overexpression M219 stable clones(M219
B7-H3) were established (Figure 6a middle and right). Cell
functional studies were carried out using these specific
modified cell lines. Initially, we explored B7-H3 role in cell
growth, and found that B7-H3 had no effect on cell growth
(data not shown). Second, we examined the effect of B7-H3
on cell migration and invasion. B7-H3 expression enhanced
cell migration and invasion (Figure 6b and c). Finally, we
performed soft agar and Matrigel three-dimensional cell
culture. Cells that were seeded on day 1 were showed in
Supplementary Figure S4 online. As shown in Figure 6d and e,
B7-H3 did not have any effect on colony formation in soft
agar, which indicated that anchorage-independent growth
was not affected by B7-H3, whereas B7-H3 enhanced cell
growth in three-dimensional culture, which further confirmed
that B7-H3 was related to cell invasion. These results
indicated that B7-H3 enhanced cell migration and invasion,
and that B7-H3 had no significant effect on cell growth.
DISCUSSION
We have demonstrated B7-H3 cell surface expression by
melanoma cells using multiple approaches to support our
hypothesis that its differential expression in advancing
stages of melanoma is prognostic. To our knowledge, this
is a previously unreported study to demonstrate that
B7-H3 expression is related to cutaneous melanoma progres-
sion and prognostic significance, as well as integrated
with tumor cell metastasis-related regulatory factors. Our
study demonstrates that B7-H3 expression is significantly
related to melanoma progression and prognosis using large
cohorts of well clinically annotated specimens with long-term
follow-up.
1338B7-H3 3′ UTR
hsa-miR-29c
5′
3′
1346
–14
0 0
40
Is
ot
yp
e
Tr
a
n
sf
e
ct
io
n 
w
ith
 m
iR
-2
9c
Tr
a
n
sf
e
ct
io
n 
w
ith
 c
on
tro
l
80
120
160
200
Co
un
ts
1 2 3
100 101 102 103 104B7-H3 IHC staining intensity
Spearman’s P = –0.4028 P = 0.0001
P =0.029
B7-H3
M1
4 m
iR-
29
c
M1
4-B
7-H
3 s
hR
NA
 1
M1
4-B
7-H
3 s
hR
NA
 2
M1
4 c
on
tro
l
M1
4 c
on
tro
l
B7-H3
p-Stat3 Cyclin D1
p-Stat3
Actin Actin
Stat3 Stat3
High (3) Low (0–1)
B7-H3 IHC staining intensity score
–13
–12
–11
–10
–9
–8
–7
–6
–5
m
iR
-2
9c
-d
Ct
M
ea
n 
flo
ur
es
ce
nt
 in
te
ns
ity
pS
TA
T 
st
ai
ni
ng
 in
te
ns
ity
Cntl
0
0100
200
300
400
500
600
3
2
1
700
800
miR-29c
Figure 5. MiR-29c regulated B7-H3 expression. (a) Binding site of miR-29c (bottom strand) to B7-H3 messenger RNA (mRNA) 30 untranslated region (UTR)
position from 1,338 to 1,346 (top strand; 9 bp in length). (b) B7-H3 immunohistochemistry (IHC) staining score versus miR-29c mRNA expression in
melanoma tissue microarray samples (paired t-test analysis). (c) Flow cytometry analysis of B7-H3 expression in a melanoma cell line with transfection of
miR-29c mimic and with a negative miRNA control (Cntl). (d) Quantitation of B7-H3 expression change after transfection with miR-29c. (e) Relationship of
IHC staining score of phosphorylated signal transducer and activator of transcription-3 (p-STAT3) versus B7-H3 in metastatic melanoma paraffin-embedded
archival tissue. (f) Western blot of STAT3 and p-STAT3 in a melanoma cell line transfected with miR-29c mimic and with negative miRNA Cntl. (g) Western
blot of STAT3, p-STAT3, and cyclin D1 in a melanoma cell lines transfected with B7-H3 small hairpin RNA (shRNA) or with shRNA Cntl.
J Wang et al.
B7-H3 Regulator of Tumor Progression
2054 Journal of Investigative Dermatology (2013), Volume 133
Studies carried out to assess tumor-infiltrating lymphocytes
CD3þ /CD8þ /CD4þ by IHC in different stages of melano-
mas show that there is no significant correlation to B7-H3
expression (data not shown). This suggests that B7-H3 may not
have a significant immunoregulatory role on melanoma cells.
The analysis of tumor-infiltrating lymphocytes or ratio to tumor
cells in relation to cancer cell B7-H3 expression has also been
inconclusive (Kobori et al., 2010).
We demonstrated an inverse correlation between miR-29c
and B7-H3 expression, and a role of miR-29c in B7-H3
regulation during melanoma progression. These findings are
novel demonstrating the functional regulatory effect by
miR29c of B7-H3 expression in melanoma cells. The func-
tional studies strongly indicate that miR-29c has a regulating
role in B7-H3 expression in relation to melanoma progression.
Based on our results, we demonstrated that miR-29c has an
important role in mediating progression of cutaneous mela-
noma through regulating B7-H3. Our studies demonstrated
that B7-H3 expression is related to cell migration and invasion
of melanoma cells using knockdown and upregulated B7-H3
melanoma cells. These findings support the functional relation
of B7-H3 expression in relation to cutaneous melanoma
progression.
p-STAT3 has various important roles in cancer including
melanoma progression (Lee et al., 2010; Jensen et al., 2011).
Previous studies have shown that downregulation of B7-H3
reduced phosphorylation of both STAT3 and its upstream
activator JAK2, whereas overexpression of B7-H3 activated
JAK2/STAT signaling. Activation of STAT3 regulates key cell
cycle molecules downstream such as cyclin D1 (Agarwal
et al., 2007). We demonstrated downregulation of p-STAT3
and cyclin D1 through B7-H3 knockdown experiments.
This confirmed studies in breast cancer whereby B7-H3
knockdwon reduces p-STAT3 activity (Liu et al., 2011).
Ipilimumab, an anti-CTLA4 mAb, can control melanoma
progression (O’Day et al., 2007; Hodi et al., 2010; Amaria
et al., 2011). Recently, studies on anti-PD1 (receptor of
B7-H1, another B7-H family member) have been successful
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in early clinical studies (Ascierto et al., 2010). These clinical
studies indicate the importance of targeting the B7-H family.
Development of therapeutics targeting B7-H3 in melanoma
may be useful for intervention. Regulation of B7-H3 ligand
binding a receptor is still not understood. Identification of the
B7-H3 receptor in melanomas may allow the development of
targeted therapies blocking the B7-H3 signaling pathway.
Recently, the TREM (triggering receptor expressed in murine
myeloid cells)-like transcript 2 was found to bind B7-H3
(Hashiguchi et al., 2008). However, these findings have not
been verified in humans and are not verified (Leitner et al.,
2009). In summary, we demonstrated that B7-H3 expression
on metastatic melanoma cells significantly correlated with
tumor progression and poor MSS in patients, and associated
with several melanoma-regulating pathways. The studies also
demonstrated that B7-H3 affected functional activity of
B7-H3-positive cells independent of immunoregulatory events.
MATERIALS AND METHODS
Cells lines and tissues
Melanoma cell lines (M-1, M-101, M-111, M-12, M-14, JK-0346
Mel-B, JH-1173, Wm266-4) were cultured in RPMI 1640 (Life
Technologies, Grand Island, NY) as previously described (Goto
et al., 2008). Melanocyte primary cultures were grown as suggested
by the manufacturer (Lonza, Newington, NH).
For protein expression by IHC analysis, PEAT specimens of primary
melanomas (n¼ 30) and metastatic melanomas (n¼ 67) were
assessed. PEAT specimens of nevi were used as controls. For mRNA
analysis, PEAT specimens of a separate cohort consisting of primary
and metastatic melanomas were assessed. All studies were conducted
blinded to the pathology and clinical status of patients. PEAT speci-
mens were obtained under a research protocol approved by the
Western Institutional Review Board.
Melanoma TMAs
As previously described (Camp et al., 2008), two melanoma TMAs
were constructed by the Department of Pathology (Dr D Rimm, Yale
University) using AJCC stage III and IV melanomas from John Wayne
Cancer Institute with annotated clinical outcome. Melanomas from
each PEAT block was identified; cores measuring 0.6 mm in diameter
were made and the TMA was constructed as previously described
(Nguyen et al., 2010). The AJCC Stage III TMA included 139 metastatic
melanoma containing LN, 10 melanoma lines, 12 histopathology
negative LN (cancer free), and 2 liver tissues to be used as controls.
The AJCC Stage IV melanoma TMA included 268 distant organ
metastases and 39 paired stage III/LN metastases from 169 melanoma
patients, as well as 29 normal tissue controls from each respective
organ (cancer free). Duplicated cores of all specimens and controls
were included in all TMAs. TMA results were analyzed by two
independent investigators.
IHC analysis of B7-H3 expression
PEAT sections were deparaffinized with xylene and rehydrated with
ethanol, before antigen retrieval (Diagnostic BioSystems, Pleasanton,
CA). Endogenous peroxidase activity was inactivated by incubation in
3.0% H2O2 (20 minutes). Nonspecific binding sites were blocked for
30 minutes with Protein Block serum free (Dako, Carpinteria, CA).
The tissue sections were incubated at room temperature with a goat
anti-human B7-H3 polyclonal antibody (Ab; 100mg ml 1;
R&D Systems, Minneapolis, MN) diluted (1:50). After washing with
phosphate-buffered saline (PBS) containing 0.1% Tween-20, the
reaction for B7-H3 was developed using a labeled streptavidin biotin
method (LSABþ Kit; Dako), and visualized using VIP Substrate Kit
(Vector Laboratories, Burlingame, CA; Yoshimura et al., 2011). The
negative controls consisted of sections treated with goat serum alone
(Santa Cruz Biotechnology, Santa Cruz, CA).
The melanoma AJCC stage II/III/IV and normal tissue IHC analysis
for B7-H3 was scored (0, 1, 2, 3) by two independent investigators.
The IHC for B7-H3 protein expression was classified as score
0 (absent), score 1 (weak), score 2 (moderate), and score 3 (strong)
by light microscopy.
IHC for p-STAT3
p-STAT3 IHC was conducted on 5-mm stage III melanoma metastasis
sections (n¼ 20). IHC was conducted following melanin bleaching
after modification (Momose et al., 2011). In brief, following
deparaffinization and rehydration, tissue was bleached with 3%
H2O2, and then subjected to antigen retrieval (Vector Laboratories).
Tissue sections were then blocked with goat serum (10%) for 1 hour
followed by incubation with rabbit anti-pY705-STAT3 mAb (Cell
Signaling, Danvers, MA) overnight at 4 1C. Ab staining was amplified
with VECTASTAIN Elite ABC Kit (Vector Laboratories). After develop-
ment with Dako diaminobenzidine (Dako) substrate, sections were
counterstained with hematoxylin and mounted. P-STAT3-stained
tissues were assessed and scored using the same method as used
for B7-H3, on a scoring scale of 0 (none), 1, 2, and 3 (strongest).
Flow cytometry
Flow cytometric analysis was performed using the BD FACS Calibur
System (BD Biosciences, San Jose, CA). After washing in buffer
containing 2% fetal bovine serum, melanoma cells (105) were
incubated at 4 1C (1 hour) with phycoerythrin-conjugated mouse
monoclonal anti-human B7-H3 Ab (R&D Systems), followed by
washing three times, then resuspended in PBS for flow cytometry,
and analyzed using Quest software (BD Biosciences). Respective
isotype-matched Ab was used as a negative control.
Immunofluorescence
Melanoma cells were cultured on Lab-Tek II chamber slides (Nalge
Nunc, Thermo Fisher Scientific, Rochester, NY) and fixed with
paraformaldehyde (4%) in PBS (10 minutes) after washing in PBS.
Melanoma cells were blocked by BSA (5%) for 30 minutes and
stained using mouse monoclonal anti-human B7-H3 Ab (R&D
Systems) and phycoerythrin-conjugated goat anti-mouse secondary
Ab (Santa Cruz Biotechnology) at room temperature for 1 hour. Slides
were mounted with Vectashield mounting medium containing 40,6-
diamidino-2-phenylindole for nuclear staining (Vector Laboratories).
Cells were analyzed using a Nikon Eclipse Ti fluorescence micro-
scope (Nikon, Irvine, CA).
RNA extraction
Tri-Reagent (Molecular Research Center, Cincinnati, OH) was
used to extract total RNA from cultured cells (Koyanagi et al.,
2006). For RNA extraction of individual PEAT specimens,
10 sections of 10-mm-thick tissues were deparaffinized with xylene
and washed with ethanol. Total RNA from PEAT specimens was
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extracted, isolated, purified, quantified as previously described
(Koyanagi et al., 2006).
Primers and probes
Primer and probe sequences of B7-H3 were designed to assess B7-H3
mRNA expression in PEAT specimens. The forward primer, fluores-
cence resonance energy transfer probe sequence, and reverse primer
were as follows: B7-H3, 50-GACAGCAAAGAAGATGATGGA-30
(forward), 50-FAM-CCTCCCTACAGCTCCTACCCTCTGG-BHQ-1-30
(probe), 50-ACCTGTCAGAGCAGGATGC-30 (reverse). The glyceral-
dehyde-3-phosphate dehydrogenase forward primer, fluorescence
resonance energy transfer probe sequence, and reverse primer
were as follows: 50-GGGTGTGAACCATGAGAAGT-30 (forward),
50-FAM-CAGCAATGCCTCCTGCACCACCAA-BHQ-1-30 (probe), and
50-GACTGTGGTCATGAGTCCT-30 (reverse).
RT-qPCR assay
All reverse transcription reactions of RNA were performed as
previously described (Koyanagi et al., 2006). The RT-qPCR assay
was performed with the iCycler iQ Real-Time Thermocycler
Detection System (Bio-Rad Laboratories, Hercules, CA). For each
reaction, complementary DNA from 250 ng of RNA was used with
the PCR reaction mixture. Samples were amplified with a precycling
hold at 95 1C (10 minutes), followed by 40 cycles of denaturation for
each marker at 95 1C (60 seconds), annealing at 63 1C (60 seconds,
B7-H3; 55 1C, glyceraldehyde-3-phosphate dehydrogenase), and
extension at 72 1C (60 seconds). Specific gene plasmids for external
controls of each gene were synthesized. Standard curves for each
assay were generated using a threshold cycle of dilutions of plasmid
containing the target gene template (106–101 copies). Copy number
analysis was performed using the iCycler iQ Real-Time Software
(Bio-Rad Laboratories). Each sample was assessed in duplicates with
positive (M14 cells) and reagent controls for RT-qPCR assays.
To demonstrate correlation between miR-29c and B7-H3, RT-qPCR
miR-29c expression data from a previous study (Nguyen et al., 2010)
were compared with B7-H3 expression of the same tissue specimens.
B7-H3 IHC score was assigned using the following scoring system:
0-none, 1-weak, 2-moderate, 3-strong. Correlation was demonstrated
using Spearman’s rank correlation test over the Pearson’s correlation
test as data demonstrated skewness. The analysis was carried out
in concordant with the minimum information for publication of
quantitative real-time PCR experiments(MIQE) guidelines (Bustin
et al., 2009).
Western blotting
Protein concentrations were determined using the Pierce BCA assay
(Thermo Scientific, Rockford, IL). Western blot was performed as
previously described (Narita et al., 2009). Membranes were
immunoblotted overnight with primary rabbit polyclonal anti-B7-H3
Ab and cyclin D1 Ab (1:1,000, Santa Cruz Biotechnology), rabbit
polyclonal anti-STAT3 and anti-p-STAT3 Ab (1:1,000, Cell Signaling)
respectively.
After immunoblotting, the membranes were washed with 3x PBS
containing 0.1% Tween-20 and followed by 1 hour incubation with
horseradish peroxidase-conjugated goat anti-rabbit Ab (1:5,000, Santa
Cruz Biotechnology) or horseradish peroxidase–conjugated rabbit
anti-mouse Ab (1:5,000, Santa Cruz Biotechnology), respectively.
Immunoreactive bands were visualized with the SuperSignal West
Dura Extended Substrate kit (Thermo Scientific) and the densities of
protein bands were quantified by Alpha Ease FCTM software (version
3.1.2, Alpha Innotech, San Leandro, CA).
Transfection of miR-29c
M14 cells, M101, and Wm266-4 were transfected in 60 mm
dishes using the Jetprime Transfection Reagent (VWR International,
Radnor, PA). Cells were seeded at 2.5–3.0 105 cells per 60 mm
dishes and transfected with 100 nmol l 1 (final) of miR-29c mimic
and negative control (Thermo Fisher Dharmacon). Dharmacon
miRIDIAN microRNA mimic is a double-stranded RNA oligonucleo-
tide, chemically modified with the Dharmacon ON-TARGET modi-
fications. Dharmacon miRIDIAN negative control is a nonhuman
miRNA with minimal sequence identity with human miRNAs.
After transfection (24 hours), cells were treated with 1 mg ml 1
Pronase E (Merck; 30 minutes; 37 1C) to strip off B7-H3 protein on
the cell surface. Newly expressed B7-H3 protein levels 48 hours after
Pronase treatment were measured by phycoerythrin-conjugated
monoclonal mouse anti-human B7-H3 Ab immunofluorescence
staining followed by flow cytometry analyses. Cells transfected
(72 hours) with 100 nmol l 1 (final concentration) of miR-29c
mimic or negative control were lysed in cold lysis buffer, followed
by western blotting.
Development of B7-H3 knockdown cells
The B7-H3 shRNA 1 sequence is 50-CCGGCTCTGAAACACTCTG
ACAGCACTCGAGTGCTGTCAGAGTGTTTCAGAGTTTTTTG-30. The
B7-H3 shRNA 2 sequence is 50-CCGGCTAGCCTTAATACTGGCCT
TTCTCGAGAAAGGCCAGTATTAAGGCTAGTTTTTTG-30. The vector
is a lentiviral construct pLKO.1-Puro (Sigma, St Louis, MO). A shRNA
that does not match any known human cDNA was used as a control.
Cells were stably transduced with B7-H3 shRNAs or the control
shRNA construct and selected in 5mg ml 1 puromycin as suggested
by manufacturer’s instructions. Pooled populations of knockdown
cells were used for the experiments.
Development of B7-H3-overexpressing cells
The human B7-H3 cDNA vector was purchased from Origene
Company (Rockville, MD). Stable cell lines, after transfection, were
selected with 800mg ml 1 G418. Pooled populations were used in all
experiments.
Cell growth and soft agar colony formation
Cell proliferation and viability was assessed by the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium assay. Three-dimen-
sional cell culture was performed using Matrigel matrix (BD
Biosciences) in a 96-well plate according to manufacturer’s instruc-
tion. A soft agar colony formation assay was performed using six-well
culture plates.
Cell migration and invasion assay
Briefly, 104 cells were plated on the top of the Boyden chamber
inserts (BD Biosciences). Serum (5%) was used as the chemoattrac-
tant. To rule out the effect of cell proliferation, 2mg ml 1 mitomycin C
was added to the cells. Cells on the lower surface of the inserts
were stained and counted using a light microscope. For invasion
assays, inserts were coated with a thin layer of Matrigel basement
membrane matrix.
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Biostatistical analysis
For PEAT specimens, the Wilcoxon rank sum test was used to assess
the difference in B7-H3 mRNA copy numbers between AJCC stage-
linked melanoma and nevi/benign lentigo melanocytes/normal skin
tissues. The Kruskal–Wallis test was used to identify AJCC stage-
related differences in B7-H3 mRNA copy numbers. Increased expres-
sion of B7-H3 in distant organ metastasis relative to their matched
lymph node metastasis was assessed by the paired t-test. MSS
analyses were conducted using the Kaplan–Meier method and
comparisons among groups were performed using log-rank tests.
Correlation analysis between miR-29c mRNA expression and B7-H3
IHC was performed using Spearman’s correlation coefficient. Statis-
tical calculations were performed using SAS statistical software (SAS,
Cary, NC); Po0.05 was considered significant.
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